ITOS – iteos therapeutics, inc. (US:NASDAQ)
Stock Stats
News
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
Form SC 13G iTeos Therapeutics, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
Form 4 iTeos Therapeutics, Inc. For: Nov 19 Filed by: Gall Matthew
Form SC 13D/A iTeos Therapeutics, Inc. Filed by: Boxer Capital Management, LLC
Form SC 13D/A iTeos Therapeutics, Inc. Filed by: Boxer Capital Management, LLC
Form SC 13G/A iTeos Therapeutics, Inc. Filed by: EcoR1 Capital, LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.